NCIRD

Katalin Karikó and Anne Schuchat Receive 2023 Fries Prize for Improving Health

Retrieved on: 
Sunday, November 12, 2023
DRS, Infant, Pneumonia, Nobel Prize, Cell, Epidemic Intelligence Service, GAVI, Immunization, CDC, Group B streptococcal infection, NCIRD, Doctor of Philosophy, USPHS, University of Szeged, COVID, Organization, Erich Fried Prize, Health, American Public Health Association, RADM, Parent, ARD International Music Competition, Letter, Public, Meningitis, RNA, Therapy, University of Pennsylvania, Anne Schuchat, Infection, APHA, University, RET, SARS, Research, Developmental Biology (journal), Death, Vaccine, Messenger, COVID-19, GBS, Nursing, Management, Pharmaceutical industry, Physiology, Ophthalmology, Medicine, MD

ATLANTA, Nov. 12, 2023 /PRNewswire/ -- Nobel Prize Winner Katalin Karikó, PhD, and former Centers for Disease Control and Prevention (CDC) Principal Deputy Director Anne Schuchat, MD (RADM, USPHS, RET), today received the 2023 Fries Prize for Improving Health.

Key Points: 
  • ATLANTA, Nov. 12, 2023 /PRNewswire/ -- Nobel Prize Winner Katalin Karikó, PhD, and former Centers for Disease Control and Prevention (CDC) Principal Deputy Director Anne Schuchat, MD (RADM, USPHS, RET), today received the 2023 Fries Prize for Improving Health.
  • The Fries Prize for Improving Health award was presented this morning at the American Public Health Association's (APHA) annual meeting, which is taking place in Atlanta.
  • The monetary award for the Fries Prize for Improving Health is $70,000, which will be divided between the recipients.
  • As of 2016, the CDC Foundation manages and administers the Fries Foundation's public health award programs, which include the Fries Prize for Improving Health and the Elizabeth Fries Health Education Award.

Palantir Expands Longstanding CDC Partnership for Disease Monitoring and Response

Retrieved on: 
Friday, April 15, 2022
Other Health, Software, General Health, Pharmaceutical, Data Management, Technology, Infectious Diseases, Hospitals, Clinical Trials, Biotechnology, FDA, Health, Integration, Immunization, Human services, National Center for Immunization and Respiratory Diseases, CDC, U.S. Securities and Exchange Commission, COVID-19, Environmental disease, Security (finance), Software, PLTR, USG, Food, System, Organization, Department, United States Department of Health and Human Services, National, Personal Data Privacy and Security Act of 2009, Securities Exchange Act of 1934, Anthrax, Program, NWSS, Forward-looking statement, NYSE, Food and Drug Administration, Degenerative disease, Public health surveillance, Public health, Daou Technology Inc., Partnership, Securities Act of 1933, COVID, Time, NCIRD, Pharmaceutical industry, Vaccine

Palantir Technologies Inc. (NYSE:PLTR) today announced an extension and expansion of its work with the U.S. Centers for Disease Control and Prevention (CDC) through the outbreak response and disease surveillance solution for the Data Collation and Integration for Public Health Event Response (DCIPHER) Program.

Key Points: 
  • Palantir Technologies Inc. (NYSE:PLTR) today announced an extension and expansion of its work with the U.S. Centers for Disease Control and Prevention (CDC) through the outbreak response and disease surveillance solution for the Data Collation and Integration for Public Health Event Response (DCIPHER) Program.
  • Over a decade ago, Palantir and the CDC initially partnered to support the agencys efforts to manage foodborne outbreaks and the partnership grew to include countering Ebola and the management of anthrax and bacterial special pathogens.
  • These initiatives are separate and distinct from Palantirs COVID-19 response work with U.S. federal health agencies.
  • We are honored to continue and expand our long-standing partnership with CDC in support of public health surveillance and outbreak response, said Dr. William Kassler, Chief Medical Officer for USG at Palantir.

SpeeDx Expand SARS-CoV-2 Variant Analysis Pipeline

Retrieved on: 
Tuesday, August 17, 2021
Biotechnology, Infectious Diseases, Health, Science, Research, Degenerative disease, Delta, Severe acute respiratory syndrome coronavirus 2, Real-time, NCIRD, Sequence analysis, National Center for Telehealth & Technology, Research, STI, Volatile organic compound, National Center for Immunization and Respiratory Diseases, Fyfe Pty Ltd, Division, Mutation, Multimedia, Respiratory disease, RNA polymerase II, Immunization, Workflow, VOC, COVID-19, Technology, Heating, ventilation, and air conditioning

Ltd., a developer of innovative molecular diagnostic solutions, have expanded their product line of research reagents for COVID-19 variant analysis to include a mutation connected to the SARS-CoV-2 Delta variant of concern (VOC).

Key Points: 
  • Ltd., a developer of innovative molecular diagnostic solutions, have expanded their product line of research reagents for COVID-19 variant analysis to include a mutation connected to the SARS-CoV-2 Delta variant of concern (VOC).
  • Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin and London, and distributors across Europe.
  • SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management.
  • For more information on SpeeDx please see: https://plexpcr.com
    SARS-CoV-2 Variant Classifications and Definitions.